Pfizer launches first human trial of experimental eczema drug
NCT ID NCT06564389
First seen Jan 15, 2026 · Last updated May 16, 2026 · Updated 23 times
Summary
This early-stage study tests a new drug, PF-07832837, in healthy volunteers and people with moderate-to-severe atopic dermatitis (eczema). The main goal is to check safety and how the body processes the drug. Researchers will also look for early signs that it might improve eczema symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anaheim Clinical Trials, LLC
RECRUITINGAnaheim, California, 92801, United States
-
Miami Dermatology and Laser Research
NOT_YET_RECRUITINGMiami, Florida, 33133, United States
-
Paddington Testing Company
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.